首页> 美国卫生研究院文献>British Journal of Cancer >Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b multicentre study

【2h】

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b multicentre study

机译：伊马替尼与磷酸肌醇激酶抑制剂Buparlisib与胃肠道间质瘤的患者组合患有伊马替尼和孙尼替尼治疗的胃肠道 - 基质肿瘤：1B阶段Multicentre研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Baseline characteristics and demographics (FAS).

机译：基线特征和人口统计（FAS）。

著录项

期刊名称 British Journal of Cancer
作者
Hans Gelderblom; Robin L. Jones; Suzanne George; Claudia Valverde Morales; Charlotte Benson; Jean-Yves Blay; Daniel J. Renouf; Toshihiko Doi; Axel Le Cesne; Michael Leahy; Sabine Hertle; Paola Aimone; Ulrike Brandt; Patrick Schӧffski;
展开▼
作者单位

展开▼
年(卷),期 2020(122),8
年度 2020
页码 1158–1165
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：胃癌;胃癌;

相似文献

外文文献
中文文献
专利

1. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST' [J] . Schoffski Patrick, Mir Olivier, Kasper Bernd, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第1期

机译：用伊马替尼和孙尼替尼治疗后转移性胃肠道肿瘤患者多靶酪氨酸激酶抑制剂Cabozatinib的活性和安全性：欧洲癌症期间审判的欧洲研究和治疗组织1317'Cabogist'
2. 7511 POSTER Safety and efficacy results of sunitinib from a worldwide treatment- use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy [J] . B.Seddon, P.Reichardt, W.Ruka, European Journal of Cancer Supplements . 2007,第4期

机译：7511 POSTER舒尼替尼的安全性和有效性结果来自对先前伊马替尼治疗有耐药性或耐受性的胃肠道间质瘤（GIST）患者（pts）的一项全球治疗使用试验
3. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial [J] . Doi Toshihiko, Kurokawa Yukinori, Sawaki Akira, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：TAS-116的功效和安全性，一种热休克蛋白90的口服抑制剂，在转移或不可切除的胃肠间质谱难以难治于伊马替尼，孙尼替尼和雷诺苯脲：II期，单臂试验
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib [O] . Y-K Kang, C Yoo, B-Y Ryoo, 2013

机译：伊马替尼和舒尼替尼治疗失败后转移性和/或不可切除的胃肠道间质瘤患者的多维替尼II期研究
6. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour [O] . Wagner Andrew J., Agulnik Mark, Heinrich Michael C., 2016

机译：第二代非安那霉素HSP90抑制剂onalespib（AT13387）与伊马替尼联合治疗转移性胃肠道间质瘤患者的剂量递增研究

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b multicentre study

摘要

著录项

相似文献

相关主题

期刊订阅